India, Nov. 4 -- Royalty Pharma plc (RPRX), the largest buyer of biopharmaceutical royalties and a major funder of life sciences innovation, reported higher third-quarter 2026 portfolio receipts and raised its full-year outlook.
Company Profile
Royalty Pharma's portfolio includes royalty interests in more than 35 commercial therapies, including Trikafta, Trelegy, Tremfya, Evrysdi, Xtandi, Voranigo and Imdelltra, along with 16 development-stage product candidates.
Q3 Financial Highlights
For the third quarter ended September 30, 2026, Portfolio Receipts increased 9% to $890 million from $814 million in the prior-year period.
Royalty Receipts increased 9% to $883 million from $811 million in the prior-year quarter, driven by higher contr...